BRPI0713814A2 - saiais monovalente e bivalente de Ácido glutamÍnico-l-n- (5-hidroxicotinoila) exibindo aÇço psicotràpica (antidepressiva e anxiolÍtica), cÉrebroprotetora e heroprotetora, neuroprotetora - Google Patents

saiais monovalente e bivalente de Ácido glutamÍnico-l-n- (5-hidroxicotinoila) exibindo aÇço psicotràpica (antidepressiva e anxiolÍtica), cÉrebroprotetora e heroprotetora, neuroprotetora

Info

Publication number
BRPI0713814A2
BRPI0713814A2 BRPI0713814-8A2A BRPI0713814A BRPI0713814A2 BR PI0713814 A2 BRPI0713814 A2 BR PI0713814A2 BR PI0713814 A BRPI0713814 A BR PI0713814A BR PI0713814 A2 BRPI0713814 A2 BR PI0713814A2
Authority
BR
Brazil
Prior art keywords
hydroxycottinoyl
heroprotective
cerebroprotective
anxiolytic
antidepressant
Prior art date
Application number
BRPI0713814-8A2A
Other languages
English (en)
Inventor
Pavel Vasilyevich Yakimuk
Sergey Vitalyevich Stovbun
Alexandr Anatolyevich Litvin
Original Assignee
Obshcheestvo S Ogranichennoy Otvetstvennostyu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39020154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0713814(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Obshcheestvo S Ogranichennoy Otvetstvennostyu filed Critical Obshcheestvo S Ogranichennoy Otvetstvennostyu
Publication of BRPI0713814A2 publication Critical patent/BRPI0713814A2/pt
Publication of BRPI0713814A8 publication Critical patent/BRPI0713814A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0713814A 2006-07-31 2007-06-06 saiais monovalente e bivalente de ácido glutamínico-l-n- (5-hidroxicotinoila) exibindo ação psicotrópica (antidepressiva e anxiolítica), cérebroprotetora e heroprotetora, neuroprotetora BRPI0713814A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2006127564/04A RU2314293C1 (ru) 2006-07-31 2006-07-31 Одно- и двухвалентные соли n-(5-гидроксиникотиноил)-l-глутаминовой кислоты, обладающие психотропным (антидепрессивным и анксиолитическим), нейропротекторным, геропротекторным и противоинсультным действием
PCT/RU2007/000304 WO2008018815A1 (fr) 2006-07-31 2007-06-06 Sels monovalents ou divalents d'acide n-(5-hydroxynicotinoyl)-l-glutaminique présentant un effet psychotrope (antidépresseur et anxiolytique), neuroprotecteur, géroprotecteur et cérébroprotecteur

Publications (2)

Publication Number Publication Date
BRPI0713814A2 true BRPI0713814A2 (pt) 2013-09-17
BRPI0713814A8 BRPI0713814A8 (pt) 2018-01-09

Family

ID=39020154

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713814A BRPI0713814A8 (pt) 2006-07-31 2007-06-06 saiais monovalente e bivalente de ácido glutamínico-l-n- (5-hidroxicotinoila) exibindo ação psicotrópica (antidepressiva e anxiolítica), cérebroprotetora e heroprotetora, neuroprotetora

Country Status (14)

Country Link
US (1) US8030493B2 (pt)
EP (1) EP2050737A4 (pt)
JP (1) JP2009545589A (pt)
KR (1) KR101439561B1 (pt)
CN (1) CN101500998B (pt)
AU (1) AU2007282178A1 (pt)
BR (1) BRPI0713814A8 (pt)
CA (1) CA2658589A1 (pt)
EA (1) EA014855B1 (pt)
MX (1) MX2009000400A (pt)
NZ (1) NZ574637A (pt)
RU (1) RU2314293C1 (pt)
UA (1) UA93269C2 (pt)
WO (1) WO2008018815A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2398761C2 (ru) * 2008-06-16 2010-09-10 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) Средства, обладающие анксиолитическими свойствами

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1368314A1 (ru) * 1984-02-22 1988-01-23 Научно-исследовательский институт фармакологии АМН СССР @ -Никотиноиламинокислоты, обладающие противогипоксической и антиамнестической активностью
RU2068408C1 (ru) * 1992-06-24 1996-10-27 Всесоюзный научный центр по безопасности биологически активных веществ (ВНЦ БАВ) СПОСОБ ПОЛУЧЕНИЯ N-АЦЕТИЛ- α -ГЛУТАМИНОВОЙ КИСЛОТЫ
RU94038232A (ru) 1994-10-10 1996-08-27 Научно-исследовательский институт фармакологии Томского научного центра РАМН Средство, улучшающее мозговое кровообращение

Also Published As

Publication number Publication date
EA200900274A1 (ru) 2009-06-30
CN101500998B (zh) 2011-06-01
KR101439561B1 (ko) 2014-09-11
US20090240059A1 (en) 2009-09-24
CN101500998A (zh) 2009-08-05
EA014855B1 (ru) 2011-02-28
UA93269C2 (en) 2011-01-25
EP2050737A4 (en) 2011-05-04
KR20090037996A (ko) 2009-04-17
WO2008018815A1 (fr) 2008-02-14
US8030493B2 (en) 2011-10-04
RU2314293C1 (ru) 2008-01-10
CA2658589A1 (en) 2008-02-14
NZ574637A (en) 2010-10-29
MX2009000400A (es) 2009-03-02
EP2050737A1 (en) 2009-04-22
JP2009545589A (ja) 2009-12-24
BRPI0713814A8 (pt) 2018-01-09
AU2007282178A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
DK2215202T4 (da) VARIANTER AF BACILLUS sp. TS-23 ALPHA-AMYLASE MED ÆNDREDE EGENSKABER
EP2252670A4 (en) AZEOTROPARTIC COMPOSITION OF 1,1,1-TRIFLUOR-3-CHLOROPROPEN AND TRANS-1,2-DICHLORETHYLENE
DK2300560T3 (da) Termisk behandling af biomasse
DK2086960T3 (da) Nye inhibitorer af glutaminylcyclase.
DK2010498T3 (da) Syntese af acylaminoalkenylenamider, der kan anvendes som substans P-antagonister
DK2211901T3 (da) Vaccination med multiple clader af h5-influenza-a-virus
DK2470518T3 (da) Esterderivater af 2,5-furandicarboxylsyre og deres anvendelse som blødgørere
ZA200808364B (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
DK2061465T3 (da) Derivater af 4-(N-azacycloalkyl)anilider som kaliumkanalmodulatorer
DK2700786T3 (da) Modifikation af overførselspassage
DK2219647T4 (da) Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-ht3- og 5-ht1a-aktivitet
DK2219469T3 (da) Modificering af enzymatisk disponerede proteiner
DK3208269T3 (da) Inhibitorer af c-fms-kinase
DK2297312T3 (da) Alpha-amylasevarianter af Bacillus subtilis og fremgangsmåder til anvendelse heraf
DK2324013T3 (da) Broforbundne piperidinforbindelser af substitueret quinoxalintype og anvendelser deraf
DK1913135T3 (da) Extracellulære polyhydroxyalkanoater frembragt af genetisk modificerede mikroorganismer
EP2190285A4 (en) BIOLOGICAL ACTIVE ANILINE COPOLYMERS
DK2344486T3 (da) Alkylthiazolcarbamatderivater, fremstilling deraf og anvendelse deraf som hæmmere af enzymet FAAH
ATE523493T1 (de) 2-(1-oxo-1h-isochinolin-2-yl) acetamid-derivate
DK2054363T3 (da) Asymmetrisk hydrogenering af 1,1,1-trifluoracetone
BRPI0907797A2 (pt) Novo uso de 3,3'-diindolimetano
DK2315755T3 (da) Syntese af dihydrothieno[3,2-d]pyrimidindioler og lignende pyrimidindioler
BRPI0916739A2 (pt) síntese e formulações de sais de mostarda de isofosforamida e análogos dos mesmos
BRPI0718376A2 (pt) Modificação cristalina de 4-(n-metil-2-cloro-5-piridilmetilamino)-2,5-di-hidrofur an-2-ona
BRPI0713814A8 (pt) saiais monovalente e bivalente de ácido glutamínico-l-n- (5-hidroxicotinoila) exibindo ação psicotrópica (antidepressiva e anxiolítica), cérebroprotetora e heroprotetora, neuroprotetora

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements